Press releases

Results from two clinical studies will be presented at the Global Congress for Minimally Invasive Gynecology (AAGL)

COGNIS® CRT-D and TELIGEN® ICD are the world's smallest and thinnest high-energy devices

Company updates third quarter financial results and full-year 2009 guidance

Third-generation drug-eluting stent now available in CE Mark countries

Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2009, as well as guidance for...

Company to webcast its conference call on October 20. Learn how to tune in

Three models of stenting system now available for palliative treatment of malignant common bile duct strictures

Study to determine which device programming strategy best minimizes the occurrence of unnecessary therapy in ICD and CRT-D patients

Agreement will settle more than a dozen lawsuits involving intellectual property in the interventional cardiology arena

Largest randomized trial to compare the use of drug-eluting stents to bare-metal stents for AMI patients

Results support benefits of paclitaxel-eluting stents in diabetic patients

Three-year TAXUS ATLAS results show safety and efficacy advantages for Boston Scientific TAXUS Liberte Stent

Both drug-eluting stents performed well in diabetic patients

Intravascular Ultrasound (IVUS) technology designed to provide physicians a 360-degree view inside the heart and coronary vessels

PLATINUM clinical program to support FDA approval of PROMUS® Element™ Stent

Scientific symposium presentations to include clinical data on TAXUS and PROMUS stents

Agreement promotes access to testing solutions for female urinary incontinence

Findings provide additional support for PCI as a viable treatment option for patients with complex coronary anatomy

The mortality reduction trend was also observed in high-risk patients with severely reduced heart function

Results of landmark heart failure trial published by New England Journal of Medicine and presented at ESC

Dr. Ken Stein to join CRM group

Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and news announcements for the European...

Final results from the MADIT-CRT trial will be presented on Tuesday, September 1

Election of Bartlett and Byrnes increases the Boston Scientific Board to 13 members

"We delivered sales and earnings at the high end of our guidance range,” Ray Elliott, President and CEO

Longest available drug-eluting stent strengthens Company's broad portfolio

System remotely monitors patients with implantable cardiac devices, gathering information on both the device and a patient's heart health status

Learn how to tune in or find the replay of the July 21 conference call

“We are confident Ray offers the right combination of experience, results and talents for Boston Scientific going forward,” said board chairman Pete Nicholas

Landmark trial shows Boston Scientific CRT-Ds slow the progression of heart failure in asymptomatic and mildly symptomatic patients NATICK, Mass., June 23 /PRNewswire-FirstCall/ -- Boston...

Presentations to feature results on pelvic floor reconstruction systems and mid-urethral sling systems

Studies to be presented on safety and efficacy of SpyGlass System for diagnostic and therapeutic procedures throughout pancreatico-biliary system NATICK, Mass., May 28 /PRNewswire-FirstCall/ --...

SpyGlass® Direct Visualization System can now be used for diagnostic and therapeutic procedures for pancreatic disease NATICK, Mass., May 28 /PRNewswire-FirstCall/ -- Boston Scientific...

"We are grateful for their service to Boston Scientific and its customers, patients and shareholders," said Pete Nicholas, Chairman of the Board

Specifically designed for treating small coronary vessels; joins the TAXUS® Express® Atom™ Stent as the only drug-eluting stents approved for small vessel use in the U.S.

Risk of death at five years is lower for aneurysm patients treated with coil embolization compared to surgical clipping

ORION clinical trial to evaluate the Company's EPIC™ Self-Expanding Nitinol Stent System for the treatment of iliac artery disease

Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of economic and quality of life outcomes,...

Boston Scientific Corporation (NYSE: BSX) today announced that Fitch Ratings has raised the Company's rating outlook to positive from stable, while...

Results support previously announced outcomes with PCI and CABG in patients with left main coronary disease

TAXUS® Element™ Drug-Eluting Stent is now available in select markets worldwide

Online tools will help physicians determine treatment strategies

Presentations to include additional analyses from the landmark SYNTAX trial

ALTITUDE analysis presented at the Heart Rhythm Society Scientific Sessions

Analysis indicates that one life is now saved for every six patients who receive an ICD

Donation marks the beginning of Company's agreement to provide the non-profit organization with CRM devices that would otherwise remain unused

Company's new lead system reduces implant size of the world's smallest and thinnest high-energy devices

Authors identify important differences between drug-eluting stent brands

Highlights of the week's events include late-breaking trial presentations from the MADIT II clinical trial and the ALTITUDE Clinical Science Program

Data from landmark trial provide important insight for physicians in treating heart attack patients

We're off to a good start on the year," said Jim Tobin, President and Chief Executive Officer

Boston Scientific today announced special items that will reduce its GAAP earnings for the first quarter

Company will webcast its April 21 call. Learn how to tune in.

Upheld District Court's decision that JNJ's Bx Velocity and Cypher Stent Systems infringe Boston Scientific's patent

Legislation will help evaluate the current state of chronic pain care in the United States

Three-year results and two-year pooled analysis presented at ACC demonstrate continued positive outcomes for both PROMUS® and TAXUS® Stents

Analysis of economic and quality of life outcomes are based on one-year data from landmark SYNTAX trial

Presentations to include additional analyses of one-year data from the landmark SYNTAX study

Upgrade follows the Moody's actions of March 12, when it raised Company's outlook to stable from negative

iCross™ designed to improve the deliverability of Company's market-leading intravascular ultrasound (IVUS) technology

Rating agency notes that Company has been able to retain market share in the DES arena while rebuilding its CRM presence with new product launches

Legislation to evaluate the current state of chronic pain care will now move to consideration by the full House

Japanese patients now have access to second-generation drug-eluting stent

Joel Fleishman to retire from Board

Adjustments reflected in the Company's Form 10-K to be filed tomorrow

Data show comparable safety for complex patients treated with TAXUS® Express2™ Stents and bypass surgery

Journal of American College of Cardiology publishes positive ATLAS clinical data

PLATINUM clinical program to evaluate PROMUS™ Element™ Platinum Chromium Stent

Q4 adjusted results in line with expectations; Company well positioned for 2009 and beyond

Product is Japan's first second-generation drug-eluting stent

Agreement stops all litigation in interventional cardiology and endovascular repair

Provides Company the opportunity to supply therapies for VA patients at risk of sudden cardiac death and bradycardia arrhythmias

Court found patent to be invalid as obvious over the prior art; Company considering its options for challenging the decision

Company will webcast its January 29 conference call

Acquisition demonstrates Company's commitment to innovation in drug-eluting stent technology

First patient enrolled in Carotid WALLSTENT® Endoprosthesis registry

First low-profile, pre-mounted stent approved specifically for use in renal arteries

New design provides more options for treating patients with complex lesions

Boston Scientific Corporation (NYSE: BSX) today welcomed passage of legislation to help active members of the U.S. armed forces and service...

Confirms clinical value and cost-effectiveness of spinal cord stimulation

Leading carotid stent in Europe and other international markets now available in the United States

"For the second consecutive quarter, we maintained our strong U.S. DES market share leadership," said President and CEO Jim Tobin

Landmark trial provides new insight for physicians

Outcomes from the study of 22,000 patients with coronary artery disease continues to show impressive safety and efficacy data

New SYNTAX Score shows similar safety and efficacy outcomes for two thirds of study's patients

Company moves up Q3 earnings release date

TAXUS® Atom™ in more than 500 accounts Company opening new PROMUS™ accounts

Joint efforts will focus on intravascular ultrasound (IVUS)

Thursday and Friday of last week saw continued heavy trading in Boston Scientific's (NYSE: BSX) stock. As anticipated in the Company's October 9th...

Two-year pooled ARRIVE data showed the TAXUS Stent reduced clinical restenosis in patients with diabetes as effectively as in patients without diabetes

New coronary stent features thin struts designed for more uniform drug delivery

TAXUS Liberte drug eluting stent, launched in Europe and other international markets in 2005, to launch in U.S. next month

Company will also present results from the ARRIVE diabetic subset analysis, the ATLAS Workhorse and Direct Stenting trials and ATLAS data on small vessels and long lesions

The recent turmoil in the financial markets and bankruptcy of Lehman Brothers triggered automatic share selling

Company to discuss these and other issues on its third quarter earnings call on October 23 at 8:00 a.m.

PERSEUS clinical program to evaluate TAXUS® Element™ Platinum Chromium Stent

Judgment against Company entered in a patent case filed in 1997; Company to appeal

Company also announces FDA approval of TAXUS® Express2™ Stent System for treatment of in-stent restenosis

Boston Scientific Corporation (NYSE: BSX) announced today a decision by the United States District Court in Delaware. The case involves a patent...

Company announced positive one-year results from the world's largest post-approval, prospective registry for a single drug-eluting stent (DES)